Primary Progressive Aphasia Clinical Trial
Official title:
Enhancing Language Function in Aphasia Using Behavioral Language Intervention
Aphasia is an acquired impairment of language, that commonly results from damage to language areas in the brain (typically the left side of the brain). This impairment is seen in many aspects of language, including understanding, speaking, reading and writing. It is estimated that about 2 million individuals are currently living with aphasia in the United States. Further, about 200,000 Americans acquire aphasia every year (National Aphasia Association, 2020). Aphasia poses significant impact on the affected individuals and their families. Behavioral treatments that target language deficits have been shown to enhance overall communication skills and life satisfaction among individuals with aphasia. Although there is evidence that suggests that treatment is efficacious for individuals with aphasia, the extent of improvement long-term coupled with the neural patterns among those individuals are largely unknown. The current study aims to investigate the efficacy of language-based treatment and its corresponding neural patterns.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 15, 2028 |
Est. primary completion date | June 30, 2027 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Present with speech-language impairment (aphasia) caused by stroke or dementia 2. A medical diagnosis of primary progressive aphasia (PPA) by a neurologist or physician 3. Are native speakers of English 4. Present with no contraindications for MRI 5. Have adequate (normal or corrected to normal) vision and hearing Exclusion Criteria: 1. Individuals diagnosed with mood, anxiety, psychotic or substance abuse disorders. 2. Individuals with highly magnetizable metallic implants, including certain dental work, may be excluded due to image quality in MRI. 3. Individuals with other neurological disorders besides the ones of interest for the study (e.g., epilepsy, Multiple Sclerosis, Parkinson's Disease) 4. Individuals with contraindications for MRI. This includes but is not limited to pacemakers, metallic cardiac pumps, valves, magnetic materials such as surgical clips, implanted electronic perfusion pumps, or any other condition that would preclude proximity to a strong magnetic field. 5. Individuals suffering from clinically significant claustrophobia 6. Severe systemic disease (e.g., renal failure) 7. Poor overall health 8. Individuals who are pregnant 9. Individuals with a history of epileptic activity in the past 12 months 10. Individuals with a personal or family history of epilepsy or other seizure disorders will not be included in the study. 11. Individuals who have had a brain surgery in the past 12. Individuals with implanted metallic skull plates or intracranial implants 13. Individuals with skin lesions or skull damage 14. Individuals who have a history of excessive use of alcohol or drugs 15. Individuals with premorbid psychiatric disease affecting communication 16. Individuals with severe non-linguistic cognitive disturbances impeding language therapy |
Country | Name | City | State |
---|---|---|---|
United States | University of Arizona | Tucson | Arizona |
Lead Sponsor | Collaborator |
---|---|
University of Arizona |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean change from baseline scores on the naming task | Mean change from baseline scores on the Boston Naming Test: Min score = 0; Max = 60; higher scores indicate better outcome | through study completion, an average of 1 year | |
Primary | Mean change from baseline scores in aphasia severity | Mean change from baseline scores on the Western Aphasia Battery: Min score = 0; Max = 100; higher scores indicate better outcome | through study completion, an average of 1 year | |
Primary | Mean change from baseline scores on the language probe task before and after each session | change on on the probe task from before the session; Min =0; Max = 100%; higher scores indicate better outcome | through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT04290988 -
Circuitry Assessment and Reinforcement Training Effects on Recovery
|
N/A | |
Recruiting |
NCT04957537 -
Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia
|
N/A | |
Completed |
NCT04045990 -
Network Modulation in Alzheimer's Disease
|
N/A | |
Completed |
NCT05860647 -
Transmagnetic Stimulation Pilot in Primary Progressive Aphasia
|
N/A | |
Recruiting |
NCT03887481 -
Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA
|
N/A | |
Completed |
NCT03728582 -
Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy
|
N/A | |
Completed |
NCT01465360 -
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
|
N/A | |
Completed |
NCT02541097 -
Preventing Language Decline in Dementia
|
N/A | |
Recruiting |
NCT00537004 -
Language in Primary Progressive Aphasia
|
||
Recruiting |
NCT05741853 -
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
|
N/A | |
Active, not recruiting |
NCT05742698 -
Nabilone for Agitation in Frontotemporal Dementia
|
Phase 2 | |
Completed |
NCT02439853 -
Communication Bridge Speech Therapy Research Study
|
N/A | |
Completed |
NCT01623284 -
PiB PET Scanning in Speech and Language Based Dementias
|
Phase 1 | |
Completed |
NCT04726527 -
Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
|
||
Completed |
NCT03076671 -
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
|
N/A | |
Completed |
NCT05537688 -
Identification of Graphic Markers of Neurocognitive Disorders (MG)
|
||
Completed |
NCT05525377 -
Better Living With Non-memory-led Dementia
|
N/A | |
Completed |
NCT02928848 -
Transcranial Direct Current Stimulation for Primary Progressive Aphasia
|
N/A | |
Completed |
NCT04939818 -
Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders
|
||
Enrolling by invitation |
NCT05368350 -
Treating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation
|
Early Phase 1 |